NanoHive is the developer of innovative, distinctive HiveTM 3D-printed spinal interbody fusion implant portfolio targeting multiple procedure approaches.
The NanoHive Medical investment opportunity:
NanoHive is the developer of innovative, distinctive HiveTM 3D-printed spinal interbody fusion implant portfolio targeting multiple procedure approaches.
The Company's Soft Titanium technology provides for load-bearing, energy-absorbing lattices that match bone mechanicsfor intraoperative fusion mass visualization
NanoHve Medical's design patents encompass core implant features targeting lattice appearance including nose & internal features, with patents in the US, Japan, Canada and the EU.
The company's investment opportunity consists of $3 million in equity.
NanoHive Medical's revenues exceeded $3.5 million for 2023, and are projected to exceed $6 million for this year, and exceed $10 million for 2025. The Company is also projecting that it will be EBITDA positive in 2025.
6000 devices have been placed to date.
For more information regarding the opportunity, contact:
Patrick O'Donnell
President and CEO
NanoHive Medical
Tel 617 750 0383
Thomas Busby
Director
Outcome Capital (The Company's financial advisor and investment banker.)
(978) 790-6347
Comments